Biohaven Ltd.
BHVN evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for BHVN—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · BHVN
Biohaven Ltd. is a clinical-stage biopharmaceutical company focused on developing therapies for neurological and other diseases, with no approved products or revenue to date and a pipeline of candidates in Phase 3 trials.
Key risk: No revenue and operating losses
BioSniper Score
Based on 5 of 6 signals
Market Cap
$2.33B
Cash Runway
9.8 moLead Asset
bhv-1300 (Phase 3)
Next Catalyst
Phase3_Topline · Oct 1, 2026Financial data as of Jun 30, 2026.
Tracking 3 pipeline candidates · 17 clinical trials · 6 catalysts for Biohaven Ltd..
Biohaven Ltd. is a clinical-stage biopharmaceutical company focused on developing therapies for neurological and other diseases, with no approved products or revenue to date and a pipeline of candidates in Phase 3 trials.
- Biohaven has not generated any revenue from product sales and has incurred significant operating losses and negative cash flows from operations since inception [sec_mda · as of 2026-08-10].
- As of June 30, 2026, the company reported cash and equivalents of $240.6 million, shareholders' equity of $134.6 million, and total debt of $259.5 million [sec].
- The company expects its cash, cash equivalents, and marketable securities to fund operations for at least one year after the issuance date of its most recent financial statements [sec_mda · as of 2026-08-10].
- Biohaven has multiple product candidates in Phase 3 clinical trials, with topline data readouts expected between late 2026 and 2028 [upcoming catalysts].
- The company will need additional funding to support its ongoing development programs and potential commercialization, and it may seek financing through equity, debt, or collaborations [sec_mda · as of 2026-05-04].
What works
- Biohaven has a pipeline of multiple product candidates in Phase 3 trials, indicating a broad development portfolio [upcoming catalysts].
- The company's cash position as of June 30, 2026 ($240.6 million) is expected to fund operations for at least one year, providing a runway to advance its programs [sec_mda · as of 2026-08-10].
- Biohaven has entered into license agreements to acquire rights to product candidates, suggesting a strategy of in-licensing to build its pipeline [sec_mda · as of 2026-08-10].
What to weigh
- Biohaven has never generated any revenue from product sales and has a history of significant operating losses and negative cash flows [sec_mda · as of 2026-08-10].
- The company has substantial debt of $259.5 million as of June 30, 2026, which may increase financial risk [sec].
- Biohaven will require additional funding to execute its business plans, and there is no guarantee that financing will be available on acceptable terms [sec_mda · as of 2026-05-04].
- The successful development and commercialization of its product candidates is highly uncertain, and the company cannot reasonably estimate the timing or costs of completing development [sec_mda · as of 2026-08-10].
From the filings
Quoted directly from source documents.
Biohaven has not generated any revenue from product sales.
“Since our inception, we have not generated any revenue and have incurred significant operating losses and negative cash flows from operations.”
SEC MD&A · August 10, 2026
Biohaven expects its cash to fund operations for at least one year.
“We expect that our cash, cash equivalents and marketable securities, as of the date of this Quarterly Report on Form 10-Q, will be sufficient to fund operating and financial commitments, and other cash requirements for at least one year after the issuance date of these financial statements.”
SEC MD&A · August 10, 2026
Biohaven will need additional funding to execute its business plans.
“To execute our business plans, we will require funding to support our continuing operations and pursue our growth strategy.”
SEC MD&A · August 10, 2026
The successful development and commercialization of product candidates is highly uncertain.
“The successful development and commercialization of our product candidates is highly uncertain.”
SEC MD&A · August 10, 2026
Catalyst timeline
- 2026-10-01 · Phase 3 Topline (taldefgrobep alfa) — Topline data from a Phase 2/3 study evaluating taldefgrobep alfa in a specific indication.
- 2026-12-01 · Phase 3 Topline (taldefgrobep alfa) — Topline data from another Phase 2/3 study of taldefgrobep alfa.
- 2027-12-01 · Phase 3 Topline (taldefgrobep alfa) — Topline data from a Phase 3 study of taldefgrobep alfa.
- 2028-09-01 · Phase 3 Topline (BHV-8000) — Topline data from a Phase 2/3 study of BHV-8000 in early Parkinson's disease.
Risks & what to watch (4)›
Key risks
- No revenue and operating losses — Biohaven has never generated product revenue and has incurred significant operating losses and negative cash flows since inception [sec_mda · as of 2026-08-10].
- Need for additional financing — The company will require additional funding to support operations and growth, and financing may not be available on acceptable terms [sec_mda · as of 2026-05-04].
- Clinical and regulatory uncertainty — The success, timing, and cost of developing and obtaining regulatory approval for product candidates are highly uncertain [sec_mda · as of 2026-08-10].
- Substantial debt burden — As of June 30, 2026, Biohaven had total debt of $259.5 million, which could strain financial resources [sec].
What to watch
- Topline data from multiple Phase 3 trials expected between October 2026 and 2028 [upcoming catalysts].
- Ability to secure additional financing through equity, debt, or collaborations to fund ongoing operations [sec_mda · as of 2026-05-04].
- Progress of preclinical and clinical development programs, including any regulatory milestones [sec_mda · as of 2026-08-10].
Sources: SEC filings · SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run Biohaven Ltd. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Biohaven Ltd. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 5 of 6 signals · derived from public data
9.8 months
D/E 29.33 · 0% dilution
Lead: Phase 2/Phase 3
3 candidates
6 upcoming, next in ~32d
No insider transactions in the last 180 days
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
274
Total value held
$1.33B
| Holder | Shares | Value |
|---|---|---|
| janus henderson group plc | 35,069,224 | $296.4M |
| blackrock, inc. | 11,222,407 | $94.9M |
| suvretta capital management, llc | 10,286,937 | $87.0M |
| stifel financial corp | 9,940,885 | $84.1M |
| state street corp | 6,618,803 | $56.0M |
| infinitum asset management, llc | 6,250,000 | $52.9M |
| stempoint capital lp | 3,188,982 | $27.0M |
| royalty pharma sub-manager, llc | 2,936,507 | $24.8M |
| d. e. shaw & co., inc. | 2,847,193 | $24.1M |
| geode capital management, llc | 2,767,763 | $23.4M |
Showing top 10 of 274 institutional holders of Biohaven Ltd.. Open the full 13F history after sign-in.
Short Interest
as of May 20, 2026- % of float
- 21.1%
- Days to cover
- 12.4
- Shares short
- 24,865,134
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
BHVN short interestGovernance
Frequently asked questions
What is the AI investment thesis for Biohaven Ltd.?
Biohaven Ltd. is a clinical-stage biopharmaceutical company focused on developing therapies for neurological and other diseases, with no approved products or revenue to date and a pipeline of candidates in Phase 3 trials.
What is Biohaven Ltd.'s lead drug candidate?
Biohaven Ltd.'s most advanced tracked candidate is bhv-1300 (Phase 3) for Graves Disease.
What is Biohaven Ltd.'s next catalyst?
Biohaven Ltd.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Phase 2/3 Multicenter, Randomization, Double-Blind, Placebo-Controlled, Study to Evaluate the Effi" — expected October 1, 2026.
Who is the CEO of Biohaven Ltd.?
Dr. Vladimir Coric M.D. is the chief executive officer of Biohaven Ltd. (BHVN).
Where is Biohaven Ltd. headquartered?
Biohaven Ltd. (BHVN) is headquartered in New Haven, CT, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.